# Meritz Securities

> Meritz Securities is a VC fund in Yongdungpo backing Health Care, Medical and Biotechnology. See 21 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Yongdungpo, South Korea
- Total investments: 21
- Last investment: Apr 2026
- Lead investor: 24%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/meritz-securities 
- Website: https://home.imeritz.com 

Meritz Securities is a VC fund in Yongdungpo focused on Health Care and Medical. meritz is a loan brokerage service that specializes in corporate finance, brokerage, and asset management.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 7 | 33% |
| Medical | 6 | 29% |
| Biotechnology | 6 | 29% |
| Pharmaceutical | 4 | 19% |
| Software | 3 | 14% |

40 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 5 | 24% |
| Series A | 4 | 19% |
| Series B | 3 | 14% |
| Venture - Series Unknown | 3 | 14% |
| Post-IPO Equity | 2 | 10% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| South Korea | 17 | 81% |
| China | 1 | 5% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| 3billion | 3billion was founded with the goal of ending the diagnostic odyssey of rare disease patients through comprehensive genetic testing. It has reduced the amount of time and cost that was previously required for genome interpretation by using bioinformatics and machine learning technology, making genome-scale rare disease genetic testing affordable forpatients in need.The company was established in 2016 and is headquartered in Seoul, South Korea. | $11.8M | Post-IPO Equity | Apr 23, 2026 |  |
| SK E&S | SK E&S is becoming a Global Clean Energy & Solution Provider through implementation of a range of businesses, ranging from upstream interests such as overseas gas field development to downstream interests, which includes power generation, district energy, and city gas. SK E&S currently operates and supplies electricity from its LNGpower plants in Gwangyang, and contributes to Korea’s national electricity procurement by introducing competitive LNG. Also, through its community energy business that produces heat and electricity simultaneously, SK E&S supplies environment-friendly and high-efficiency energy to domestic and industrial users. Its seven city gas subsidiaries located throughout the nation supply gas with safety management as its utmost priority. | $2.1B | Private Equity | Sep 25, 2025 |  |
| SK on | SK on develops and manufacturers high-energy density electric vehicle batteries. | $1.4B | Debt Financing | Jul 30, 2025 |  |
| PEOPLE & TECHNOLOGY | PEOPLE AND TECHNOLOGY provides DX-based AI solutions on INDOOR GEOLOCATION AND SMART SENSING through its INDOORPLUS+ IoT, Location Based System (LBS) and Real Time Location System (RTLS) platform in the fields of healthcare, manufacturing, defense, smart cities, and the public sector.More than 100 corporate customers in various business sectorssuch as healthcare, banking, manufacturing, retail, energy and public services have already chosen PEOPLE AND TECHNOLOGY to deploy industry grade solutions for employee safety, asset tracking & monitoring, security & access control, flow management and process efficiency. They have gained improvements in productivity and process efficiency while reducing their corporate risks and optimizing their procurement. Since its foundation in 2013, PEOPLE AND TECHNOLOGY has become a leading provider in South Korea and is expanding overseas. | $5.1M | Series C | May 21, 2025 |  |
| Dime Bio | Dime Bio is a drug development company for novel dementia treatments. | $8.2M | Series A | Mar 26, 2025 |  |
| FNCT Biotech | FNCT Biotech develops antibody therapeutics for treating idiopathic pulmonary fibrosis (IPF). To create antibodies that target the underlying cause of IPF, the company's platform uses genetic engineering, providing patients with this medical need with a new treatment option. | $4.2M | Series A | Jan 20, 2025 |  |
| LDCarbon Co. | LD Carbon manufactures recycled resource materials designed to reduce carbon dioxide emissions. The company's eco-friendly material is manufactured by refining, processing, and commercializing combustion residues from combustion residues gas, oil, and steel that are generated through pyrolysis after crushing waste tires, enabling clients torecycle resource materials that reduce emissions, use crude oil resources, and solve environmental problems caused by waste tires for a sustainable future. | $29M | Series C | Jun 18, 2024 |  |
| Lanvin Group | Lanvin group is a fashion industry that oversees the labels lanvin, caruso, wolford, sergio rossi, and st. John knits. It is offering this assistance along with in-depth information about and connection to the fashion markets. | $15M | Post-IPO Equity | Jan 26, 2024 |  |
| FNCT Biotech | FNCT Biotech develops antibody therapeutics for treating idiopathic pulmonary fibrosis (IPF). To create antibodies that target the underlying cause of IPF, the company's platform uses genetic engineering, providing patients with this medical need with a new treatment option. | $1.5M | Series A | Oct 10, 2023 |  |
| Lanvin Group | Lanvin group is a fashion industry that oversees the labels lanvin, caruso, wolford, sergio rossi, and st. John knits. It is offering this assistance along with in-depth information about and connection to the fashion markets. | $130M | Post-IPO Equity | Dec 14, 2022 |  |

10 of 21 investments shown.

## Co-investors
- [Meritz Securities](https://shizune.co/investors/profile/meritz-securities) — VC Fund, 11 deals together
- [Industrial Bank of Korea](https://shizune.co/investors/profile/industrial-bank-of-korea) — VC Fund, 3 deals together
- [Daishin Securities](https://shizune.co/investors/profile/daishin-securities) — VC Fund, 2 deals together
- Hanyang Securities — VC Fund, 2 deals together
- [IBK Capital](https://shizune.co/investors/profile/ibk-capital-951b) — VC Fund, 2 deals together
- [Kingo Investment Partners](https://shizune.co/investors/profile/kingo-investment-partners) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Meritz Securities invest in?

Meritz Securities invests primarily in Health Care, Medical and Biotechnology startups, most often at Series C and Series A stage. Most of the 21 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Meritz Securities last invest?

The most recent investment recorded for Meritz Securities closed in Apr 2026. Shizune tracks 21 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co